CSPC Pharmaceutical Group 将来の成長

Future 基準チェック /16

CSPC Pharmaceutical Group利益と収益がそれぞれ年間2.7%と3.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に10.3% 2%なると予測されています。

主要情報

2.7%

収益成長率

2.0%

EPS成長率

Pharmaceuticals 収益成長	10.8%
収益成長率	3.8%
将来の株主資本利益率	10.3%
アナリストカバレッジ	Good
最終更新日	19 Nov 2024

今後の成長に関する最新情報

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29

Recent updates

Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

Nov 15

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Oct 16

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Sep 30

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12

業績と収益の成長予測

SEHK:1093 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	33,915	5,953	5,192	N/A	25
12/31/2025	32,273	5,626	4,680	N/A	28
12/31/2024	30,605	5,209	4,270	N/A	24
9/30/2024	30,271	5,157	N/A	N/A	N/A
6/30/2024	31,654	5,927	2,672	4,284	N/A
3/31/2024	32,380	6,057	N/A	N/A	N/A
12/31/2023	31,450	5,873	2,290	4,179	N/A
9/30/2023	31,306	6,118	N/A	N/A	N/A
6/30/2023	31,407	6,092	1,934	4,690	N/A
3/31/2023	31,116	6,116	N/A	N/A	N/A
12/31/2022	30,937	6,091	4,922	7,627	N/A
9/30/2022	30,721	5,738	N/A	N/A	N/A
6/30/2022	29,655	5,509	4,094	6,151	N/A
3/31/2022	29,007	5,538	N/A	N/A	N/A
12/31/2021	27,867	5,605	2,887	4,637	N/A
9/30/2021	26,369	5,977	N/A	N/A	N/A
6/30/2021	26,175	5,908	5,865	7,053	N/A
3/31/2021	25,551	5,472	N/A	N/A	N/A
12/31/2020	24,942	5,160	5,362	6,740	N/A
9/30/2020	24,558	4,421	N/A	N/A	N/A
6/30/2020	23,515	4,150	3,129	4,614	N/A
3/31/2020	22,735	3,922	N/A	N/A	N/A
12/31/2019	22,103	3,714	1,835	3,784	N/A
9/30/2019	21,335	3,625	N/A	N/A	N/A
6/30/2019	20,135	3,454	1,370	3,743	N/A
3/31/2019	18,835	3,294	N/A	N/A	N/A
12/31/2018	17,717	3,081	1,922	3,795	N/A
9/30/2018	16,877	2,905	N/A	N/A	N/A
6/30/2018	15,729	2,734	N/A	3,352	N/A
3/31/2018	13,959	2,443	N/A	N/A	N/A
12/31/2017	12,877	2,307	N/A	2,738	N/A
9/30/2017	12,203	2,195	N/A	N/A	N/A
6/30/2017	11,659	2,068	N/A	2,811	N/A
3/31/2017	11,383	1,979	N/A	N/A	N/A
12/31/2016	11,075	1,881	N/A	2,611	N/A
9/30/2016	10,439	1,711	N/A	N/A	N/A
6/30/2016	10,118	1,607	N/A	2,147	N/A
3/31/2016	9,656	1,473	N/A	N/A	N/A
12/31/2015	9,545	1,395	N/A	1,884	N/A
9/30/2015	9,284	1,305	N/A	N/A	N/A
6/30/2015	9,072	1,192	N/A	1,192	N/A
3/31/2015	8,919	1,126	N/A	N/A	N/A
12/31/2014	8,762	1,015	N/A	1,445	N/A
9/30/2014	8,423	896	N/A	N/A	N/A
6/30/2014	8,197	849	N/A	1,059	N/A
3/31/2014	8,001	814	N/A	N/A	N/A
12/31/2013	7,768	760	N/A	636	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1093の予測収益成長率 (年間2.7% ) は貯蓄率 ( 2.3% ) を上回っています。

収益対市場: 1093の収益 ( 2.7% ) Hong Kong市場 ( 11.6% ) よりも低い成長が予測されています。

高成長収益: 1093の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 1093の収益 ( 3.8% ) Hong Kong市場 ( 7.8% ) よりも低い成長が予測されています。

高い収益成長: 1093の収益 ( 3.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1093の自己資本利益率は、3年後には低くなると予測されています ( 10.3 %)。

CSPC Pharmaceutical Group 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased by 9.8% to HK$8.59

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

Recent updates

Executive Chairman recently bought HK$2.0m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of HK$0.16 per share

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares.

Executive Chairman recently bought HK$4.6m worth of stock

CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval

Investor sentiment deteriorates as stock falls 17%

Executive Chairman recently bought HK$6.7m worth of stock

Price target decreased by 9.8% to HK$8.59

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of HK$0.14 per share

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Executive Chairman exercised options to buy HK$52m worth of stock.

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

Investor sentiment improves as stock rises 19%

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)